Science Corporation has moved closer to its inaugural human brain implant trial by bringing on Dr. Murat Günel, chair of Yale Medical School’s Department of Neurosurgery, as scientific adviser. The brain-computer interface startup, led by former Neuralink president Max Hodak, recently secured $230 million in Series C funding at a $1.5 billion valuation as it prepares to test its distinctive approach to neural interfaces.
The company’s technology represents a fundamental departure from existing brain-computer interfaces. Rather than relying on metal electrodes that gradually damage brain tissue, Science Corporation has developed a biohybrid sensor that incorporates lab-grown neurons to create seamless communication between electronics and the human brain. This biological integration allows the device to function naturally within neural tissue and respond to light-based stimulation, potentially solving the long-term biocompatibility issues that have plagued traditional neural implants.
Science Corporation is simultaneously advancing PRIMA, its treatment for blindness caused by macular degeneration, which is expected to receive European regulatory approval within the year. The dual-track development strategy positions the company to enter multiple therapeutic markets as brain-computer interfaces transition from experimental demonstrations to practical medical applications. While researchers have already proven these systems can help patients with ALS and spinal cord injuries regain motor control, the commercial path forward remains challenging due to complex regulatory requirements and relatively small patient populations.
This breakthrough signals that the brain-computer interface field is maturing beyond proof-of-concept demonstrations toward sustainable, long-term neural integration technologies that could unlock entirely new categories of neurological treatments.
TECHCRUNCH AI ↗